NewsBenzingaHC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $130 HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $130 Benzinga 2026.10.08 12:24 (GMT+0) Open on Benzinga Other news Morgan Stanley Maintains Underweight on Lazard, Lowers Price Target to $41 Wells Fargo Maintains Overweight on BlackRock, Lowers Price Target to $1230 RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $345 Wells Fargo Maintains Equal-Weight on Levi Strauss, Lowers Price Target to $20 Jeff Bezos Could Take Blue Origin Public. Amazon Investors Just Got a New Space Question Morgan Stanley Maintains Overweight on Houlihan Lokey, Lowers Price Target to $165
